Atai Beckley is working with advisers to explore options for its flagship psychedelic drug candidate, according to people familiar with the matter
TL;DR
Atai Beckley is exploring strategic options for its flagship psychedelic drug BPL-003, targeting treatment-resistant depression with FDA Breakthrough Therapy designation and preparing for Phase 3 trials. The company has cash reserves to fund operations through 2029, supporting its pipeline including other assets like EMP-01 and VLS-01 for mental health conditions.
Atai Beckley is working with advisers to explore options for its flagship psychedelic drug candidate, according to people familiar with the matter
Atai Beckley N.V. (NASDAQ: ATAI), formed through the 2025 merger of atai Life Sciences and Beckley Psytech, is advancing its pipeline of psychedelic-based therapies for mental health conditions while engaging advisers to evaluate strategic options for its lead candidate, BPL-003 (mebufotenin benzoate nasal spray). The company's flagship program, which targets treatment-resistant depression (TRD), has received Breakthrough Therapy designation from the FDA and is preparing for a Phase 3 trial following an End-of-Phase 2 meeting with regulators. BPL-003 is designed to deliver rapid antidepressant effects within a two-hour interventional psychiatry model and is supported by granted patents in multiple jurisdictions.
Recent phase 2a data for EMP-01 (R-MDMA), another key asset in development for social anxiety disorder, showed a 11.8-point reduction in anxiety severity on the Liebowitz Social Anxiety Scale compared to placebo, though the stock declined 14% post-announcement as investors sought stronger efficacy signals. Analysts at Berenberg described EMP-01 as a "high-risk, high-reward" candidate with a modeled 5% probability of achieving $4 billion in global peak sales, driven by unmet needs in a market targeting 20 million U.S. patients.
Atai Beckley's cash reserves, bolstered by a $150 million public offering in October 2025, are projected to fund operations through 2029, covering anticipated Phase 3 data for BPL-003 and Phase 2 results for VLS-01 (DMT buccal film) in late 2026. The company's leadership team, including CEO Srinivas Rao and a board with biotech and psychiatric expertise, emphasizes a focus on scalable treatments for severe mental health conditions. While challenges persist in psychedelic drug development—including regulatory scrutiny and competition, the company remains positioned to advance its pipeline amid growing interest in neuroplastogens for mental health.
